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ABSTRACT
Background
Chronic renal failure patients are at particular risk of hepatitis B virus infection. Early studies have demonstrated that renal failure
patients benefit from vaccination; however, not all studies have consistently shown benefit.
Objectives
To determine the beneficial and harmful effects of hepatitis B vaccine and of a reinforced vaccination series in chronic renal failure
patients.
Search methods
We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Renal Group Controlled Trials Register, The
Cochrane Controlled Trials Register on The Cochrane Library (Issue 1, 2002), PubMed/MEDLINE (1966 to July 2003), EMBASE (1985
to November 2003), Current Clinical Practice Guidelines (Canadian Immunization Guide and Vaccine Preventable Diseases Surveillance
Manual), and Science Citation Index as well as journals, published abstracts, and reference lists of articles.
Selection criteria
Randomised clinical trials comparing plasma vaccine with placebo, recombinant vaccine with placebo, recombinant vaccine with plasma
vaccine, and a reinforced vaccination series (ie, more than three inoculations) with three inoculations of vaccine in chronic renal failure
patients.
Data collection and analysis
Primary outcome measures included incidence of patients developing hepatitis B virus antibodies and infections while secondary
outcomes included adverse events, liver-related morbidity, and mortality. Random effects models were used and reported relative risks
and 95% confidence intervals (RR and 95% CI).
Hepatitis B vaccination for patients with chronic renal failure (Review)
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Main results
We included seven randomised clinical trials. None of them had high quality. Plasma vaccine was significantly more effective than
placebo in achieving hepatitis B antibodies (RR 23.0, 95% CI 14.39 to 36.76, 3 trials). We found no statistically significant difference
between plasma vaccine or placebo regarding hepatitis B virus infections (RR 0.50, 95% CI 0.20 to 1.24). We found no statistically
significant differences between recombinant vaccine and plasma vaccine in achieving hepatitis B antibodies (RR 0.65, 95% CI 0.28 to
1.53, 2 trials). Heterogeneity was significant and appeared to be attributable to the dose of vaccine. Two trials examined a reinforced
recombinant vaccine strategy, which was not statistically more effective than three inoculations of recombinant vaccine regarding
development of hepatitis B antibodies (RR 1.36, 95% CI 0.85 to 2.16).
Authors’ conclusions
Plasma derived vaccines are more effective than placebo in achieving hepatitis B antibodies, while no statistically significant difference
was found between recombinant and plasma vaccines. No statistically significant difference of effectiveness was observed between a
reinforced vaccination series versus routine vaccinations of three inoculations of recombinant vaccine.

PLAIN LANGUAGE SUMMARY
Hepatitis B vaccines achieve antibody production in patients with chronic renal failure, but we do not know if the vaccines are
protective
Patients with chronic renal failure are at increased risk of hepatitis B virus infections. This review was undertaken to determine the
beneficial and harmful effects of vaccination against hepatitis B and of a reinforced recombinant vaccination series. None of the trials
had high methodological quality. Plasma vaccine was significantly more effective than placebo in achieving hepatitis B antibodies. Yet
no statistically significant difference was found between the use of plasma vaccine or placebo in preventing hepatitis B virus infections.
No trials comparing recombinant vaccine with placebo were identified. There was no significant difference between recombinant and
plasma vaccines or between a reinforced vaccination series and routine vaccinations of three inoculations using recombinant vaccine
regarding achieving hepatitis B antibodies.

BACKGROUND
Hepatitis B virus (HBV) is one of the most frequent viral infections in humans with estimates of 200 to 500 million infected
people worldwide (Specter 1999; Fabrizi 2000). Infection can occur either through perinatal transmission, which is the cause of 35
to 40 per cent of new infections worldwide (Fabrizi 2000) or horizontally through exposure to infected blood or other body fluids.
While the perinatal (vertical) mode of transmission is of increasing concern in specific geographic regions (Fabrizi 2000) much
more attention has been focused on the horizontal transmission of
the HBV among high-risk populations. The high-risk population
for horizontal transmission includes health-care workers, chronic
renal failure (CRF) patients (Torres 1996; Jefferson 2000), and
homosexual men (MacKellar 2001).
CRF patients are at particular risk of HBV infection due to their
increased exposure to blood products, haemodialysis (Crosnier
1981; Desmyter 1983; Jilg 1986a; Seaworth 1988a; Dukes 1993;

El-Reshaid 1994; Jungers 1994a), and an impaired immune
response (Revillard 1979; Chatenoud 1986; Chatenoud 1990;
Johnson 1992). The impaired immune response affects hepatitis
B vaccine efficacy. Cases of infections among renal patients undergoing dialysis are generally mild, but up to 80 per cent may
progress into chronic carriers. This poses risk to other haemodialysis recipients in the same clinical facility (Desmyter 1983; Stevens
1984; Huang 1997). Liver-related morbidity including cirrhosis and hepatocellular carcinoma may also develop. Occurrences
of chronic hepatitis in the haemodialysed populace have ranged
from 3 to 29 per cent (Huang 1997) and the estimated prevalence
of HBV infection has previously been reported to be 1.1 to 6.1
per cent in dialysis patients worldwide (Geerlings 1991; Petrosillo
1993; Tokars 1998). Current data from the United States indicate that the prevalence of HBV infections among those receiving
maintenance haemodialysis is 0.9 per cent (Tokars 2000) while
the prevalence of HBV infections among dialysis patients in the
developing world range from 12 to 21.6 per cent (Fabrizi 2001).
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Transmission of hepatitis B may be prevented through the administration of hepatitis B vaccine to persons at risk. The first hepatitis vaccine was derived from pooled hepatitis B surface antigen
positive plasma and was licensed in the United States of America
in 1981 (Fabrizi 2000). Today, recombinant vaccines have largely
replaced it (Jilg 1986a; El-Reshaid 1994; Zannolli 1997).
Vaccination efficacy of hepatitis B vaccine may be determined by
measuring the serum titres of antibody to the hepatitis B surface
antigen (HBsAg). Seroconversion can be used as surrogate marker
for protection against hepatitis B (Popper 1990). Titres greater
than 10 milli international units per millilitre (mIU/mL, ie, 10
IU/L) or greater than 10 Sample Ratio Units (SRU) are generally considered protective (Popper 1990). While seroconversion is
generally a useful surrogate marker, for some populations it may
be inadequate thus necessitating the study of both seroconversion
and HBV infections. A systematic review of effectiveness of these
vaccines in health-care workers (Jefferson 2000) has shown benefits. Early studies have demonstrated that renal-failure patients
benefit from vaccination. However, many have incomplete seroconversion with rates ranging from 32 to 80 per cent, and not all
studies have consistently shown benefit (Fabrizi 2000). The Advisory Committee on Immunization Practices recommends a fourdose schedule of recombinant Engerix B (40 µg) vaccine in renal
patients over 20 years of age (Rangel 2000). The current Center
for Disease Control (CDC) recommendations for vaccination of
renal patients over 20 years of age also specifies a four dose recombinant vaccine schedule of 40 µg Engerix B at 0, 1, 2, and 6 months
(CDC 2001). Various strategies employed in HBV vaccination
in this population include increased doses of vaccine, reinforced
vaccination strategies, and different schedules of vaccine administration (Jilg 1986a; Seaworth 1988a; El-Reshaid 1994). Trials
which have investigated variations in vaccine dose, dose scheduling, and the use of adjuvants to enhance seroconversion rates have
had variable results (Fabrizi 2000). Thus the optimum strategy for
immunizing CRF patients is not clear.
We have been unable to identify systematic reviews or meta-analyses on hepatitis B vaccination for CRF patients. This systematic
review investigates the effectiveness and safety of hepatitis B vaccination in providing adequate seroconversion in CRF patients and
preventing hepatitis B infections.

OBJECTIVES
• To identify the beneficial and harmful effects of hepatitis B
vaccine in CRF patients.
• To identify the beneficial and harmful effects of a reinforced
vaccination series (three inoculations plus one or more booster
inoculations) against a vaccination series of three inoculations
using hepatitis B vaccine.

METHODS

Criteria for considering studies for this review

Types of studies
Inclusion criteria
• Randomised clinical trials studying the administration of
hepatitis B vaccine to CRF patients, with or without dialysis.
• No language, publication date, or publication status
restrictions were imposed.
Exclusion criteria
• Quasi-randomised trials.
Types of participants
Inclusion criteria
• Participants of any age with CRF or receiving dialysis
(haemodialysis or peritoneal dialysis) were considered. CRF was
defined as serum creatinine greater than 200 µmol/L for a period
of more than six months or individuals receiving dialysis
(haemodialysis or peritoneal dialysis).
• Participants who were seronegative for HBsAg and
seronegative for anti-HBsAg antibodies or unsuccessfully
vaccinated against HBV (< 10 SRU, < 10 mIU/mL, < 10 IU/L,
or equivalent) (Popper 1990; Alexander 1998) prior to vaccine
administration were included (See Additional Tables 01 and 02).
Exclusion criteria
• Renal transplant patients were excluded from this review as
these individuals are immunosuppressed and are receiving
immunosuppressant agents to prevent rejection of their
transplanted organs (Johnson 1992; Lefebure 1993; Huang
1997; Fivush 1998), and they have essentially normal renal
function (Feuerhake 1984).
• Participants infected with the HBV or with evidence of
potential infection (elevated transaminases) were excluded.
Types of interventions
Inclusion criteria
• Trials comparing the beneficial and harmful effects of
hepatitis B vaccines with adjuvant or cytokine co-interventions.
• Trials comparing the beneficial and harmful effects of
immunoglobulin prophylaxis. This review was limited to studies
looking at active immunization.
• Hepatitis B vaccines (plasma or recombinant (yeast)
derived) of all types, dose, and regimens versus placebo, control
vaccine, or no vaccine.
• Reinforced schedules of vaccine of three inoculations plus
one or more booster inoculations versus standard vaccination
with three inoculations of vaccine.
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Types of outcome measures
Primary outcome measures
• Seroconversion, ie, proportion of patients with adequate
anti-HBs response (> 10 IU/L or SRU) (Table 1; Table 2).
• Hepatitis B infections (as measured by hepatitis B core
antigen (HBcAg) positivity or persistent HBsAg positivity), both
acute and chronic. Acute (primary) HBV infections were defined
as seroconversion to HBsAg positivity or development of IgM
anti-HBc. Chronic HBV infections were defined as the
persistence of HBsAg for more than six months or HBsAg
positivity and liver biopsy compatible with a diagnosis or chronic
hepatitis B.
Secondary outcome measures
• Adverse events of hepatitis B vaccinations were recorded
and were categorized as:
i) Local injection-site adverse events (as defined in included studies).
ii) Systemic adverse events.
• Liver-related morbidity (elevated transaminases, cirrhosis,
hepatocellular carcinoma).
• Mortality.
Where outcomes were reported at various intervals during the randomised trials, we analysed the outcomes reported at the longest
period following vaccinations.

Search methods for identification of studies
• We searched The Cochrane Hepato-Biliary Group Controlled
Trials Register, The Cochrane Renal Group Controlled Trials
Register, and The Cochrane Controlled Trials Register (Cochrane
Library Issue 1, 2002) were searched.
• We conducted electronic searches utilizing PubMed/
MEDLINE (1966 to July 2003) and EMBASE (Excerpta Medica
Database) (1985 to 2003) databases (see Appendix 1 for the
search strategies and MESH terms utilized). Both MESH and
non-MESH terms were used.
• We searched Science Citation Index (Web of Science)
utilizing search terms similar to those used for the PubMed/
MEDLINE and EMBASE searches.
• We searched published abstracts and proceedings from key
scientific conferences of renal, hepatology, and immunology
societies to identify any trials not published in journal format.
This included the Journal American Society of Nephrology,
Nephrology Dialysis Transplant - European Dialysis Transplant
Association, Hepatology, Journal of Hepatology,American Association
for the Study of Liver Diseases, and Vaccine from 1980 to 2002.
• We searched current clinical practice guidelines (Canadian
Immunization Guide and Vaccine Preventable Diseases Surveillance
Manual) for relevant randomised clinical trials.

• We hand searched reference lists from review articles
retrieved from PubMed/MEDLINE and reference lists from
randomised clinical trials to identify additional trials.

Data collection and analysis
Application of inclusion criteria
We conducted this systematic review and reported findings according to the ’Quality of reporting of meta-analysis guidelines’ (QUORUM) (Moher 1999; Walker 1999) and according to the recommendations of The Cochrane Collaboration in The Cochrane Reviewers’ Handbook (Clarke 2001).
• We assessed titles of research articles retrieved from the
electronic database and hand searches to determine which
abstracts should be reviewed for possible inclusion as per the
reviewers defined eligibility criteria described under ’Types of
studies’, ’Types of participants’, ’Types of interventions’, and
’Types of outcome measures’.
• All abstracts were assessed using the eligibility criteria
proposed by the reviewers for selecting papers.
• We listed excluded trials with the reasons for exclusion.
• We resolved discrepancies between individual reviewers
through consensus.
Data extraction
We performed data extraction on all randomised clinical trials
meeting eligibility criteria and review objectives. To ensure accuracy, a minimum of three reviewers independently extracted data
from each trial.
Data extraction included:
(1) Number of participants in each randomised controlled trial
and the number enrolled to receive each intervention.
(2) Demographic composition and baseline clinical information
for each intervention group. This included, when specified, age,
gender, stage of renal disease, dialysis status (haemodialysis, peritoneal dialysis, and average number of years on dialysis), previous vaccination status (previous vaccination attempts, previously
unvaccinated, or unknown), previous antigen status before receiving trial intervention (HBsAg negative, anti-HBsAg negative), and
participant withdrawals or dropouts.
(3) Types of interventions employed (plasma vaccine versus
placebo, recombinant vaccine versus plasma vaccine, reinforced
vaccination series (three inoculations plus one or more booster
inoculations)) versus standard vaccination series (three inoculations).
(4) Information relating to the vaccines (or placebo), the trade
name, dose, number of doses utilized in the trial, the immunization
schedules utilized (in months, with first inoculation = 0 months),
and route of vaccination if indicated.
(5) Information concerning the primary outcomes utilized in each
included randomised clinical trial, the type of immunoassay employed, and the time of assessment of outcomes.
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(6) Primary outcomes collected included the definition of seroconversion in each trial (SRU or IU/L) and the number seroconverted
in each group, the definition of partial seroconversion, and the
number partially seroconverted if given, and the number of active
hepatitis B infections in each group (both acute and chronic).
(7) Secondary outcomes collected included the number of adverse
events, deaths, and liver-related morbidity.
Methodological quality
The methodological quality, defined as the confidence that the
design and report will restrict bias in the intervention comparison (Moher 1998), was evaluated independently and unblinded
by a minimum of two reviewers. According to empirical evidence
(Schulz 1995; Jadad 1996; Kjaergard 2001; Jüni 2001), we assessed the methodological quality of all randomised clinical trials
meeting the criteria and objectives of this review by using separate
components, ie, generation of the allocation sequence, allocation
concealment, blinding, follow-up, and use of intention-to-treat
analyses. Components were assessed as adequate, unclear, or inadequate:
(1) Generation of the allocation sequence: adequate (computer
generated random numbers or similar), or unclear (not described),
or inadequate (other methods).
(2) Allocation concealment: adequate (central independent unit,
sealed envelopes, or similar), or unclear (not described), or inadequate (open table of random numbers or similar). In the Table of
Characteristics of Included Studies A = adequate, B = unclear, C
= inadequate.
(3) Blinding: adequate (double blind (blinding of both participants and investigators) and identical placebo tablets or similar),
or unclear (not described), or not performed (tablets versus injections, or similar).
(4) Follow-up: adequate (number and reasons for dropouts and
withdrawals described), or unclear (if the report gave impression
that there had been no dropouts or withdrawals, but this was not
specifically stated), or inadequate (number or reasons for dropouts
and withdrawals were not described).
Statistical analysis
We entered data extracted from included randomised controlled
trials into Review Manager 4.2.6. software for statistical analysis.
The random effects model was used. Data synthesis was carried
out as follows:
- Relative risk and 95% confidence intervals were computed.
- Chi-squared testing for heterogeneity was performed. A P value
of 0.1 was selected (Engels 2000).
- Homogeneity of interventions, participants, and outcomes was
assessed prior to combining extracted data from different included
randomised clinical trials being compared.
- Variability among trial results was expected, and possibilities included dose, route, frequency, and timing of vaccine administration, along with the populations reported, and the length of follow-up.
- Significant heterogeneity encountered required explanation by

the reviewers.
- The reviewers exercised caution when facing the dilemma of low
methodological quality for a significant number of included trials.
- The results were analysed with intention-to-treat analyses to
study beneficial effects.
- Where comparisons involved a small number of included trials,
caution was exercised when interpreting meta-analyses..
- ’Subgroup analysis’ was performed in cases where comparisons
between interventions being considered demonstrated significant
heterogeneity.

RESULTS

Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies.
Following the PubMed electronic database search using the search
strategy (Appendix 1), we conducted a title search on 954 listed
citations, of which 171 abstracts were reviewed. We retrieved one
hundred eight full text journal articles including both trials (n =
75) and review articles (n = 33). Only 12 articles were randomised
clinical trials that met the criteria for this review. These articles
described a total of seven randomised trials.
We conducted a subsequent modified search strategy to detect
randomised clinical trials in PubMed, which resulted in 23 unique
trials. We then reviewed titles and abstracts of these and obtained
five full text articles. However, none met the inclusion criteria.
We searched reference lists of identified journal articles but did
not identify any additional trials meeting our inclusion criteria.
An electronic search of EMBASE retrieved 772 titles, of which
102 abstracts were reviewed. Eighty-six full articles were reviewed;
however, none met our inclusion criteria.
The Web of Science electronic search (Science Citation Index) produced 10 titles of which four abstracts were reviewed. No unique
randomised trials were found.
Thus we excluded a total of seven randomised clinical trials from
this review while another seven met the specified objectives and
inclusion criteria. Three trials investigated plasma vaccines versus
placebo (Crosnier 1981; Desmyter 1983; Stevens 1984). Two trials
investigated the comparison of recombinant and plasma vaccines
(Jungers 1994a; Seaworth 1988a). Another two trials compared
a reinforced schedule of recombinant vaccine with a vaccination
series of three inoculations of recombinant vaccine (El-Reshaid
1994; Jilg 1986a) (See Table of Characteristics of Included Studies).
Plasma derived hepatitis B vaccine versus placebo
Crosnier 1981
This randomised, double-blinded, placebo-controlled trial reported the use of plasma vaccine (Institut Pasteur Production Vac-
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cine) 5 µg versus placebo, both administered at 0, 1, and 2 months.
Participants were haemodialysis patients. Outcomes included seroconversion, HBV infections, and adverse events at 12 months.
Desmyter 1983
This randomised, double-blinded, and placebo-controlled investigated heat-inactivated (CLB) plasma vaccine 3 µg versus placebo
for haemodialysis recipients. Inoculations were performed at 0, 1,
2, and 4 months. Outcomes included seroconversion, partial seroconversion, HBV infections, and adverse events at approximately
14 months.
Stevens 1984
This randomised trial of haemodialysis patients involved the comparison of Heptavax B vaccine 40 µg at 0, 1, and 6 months against
placebo. Outcomes reported included seroconversions and HBV
infections at 24 months.
Recombinant vaccine versus plasma vaccine
Jungers 1994
This randomised trial involved chronic uremic patients. GenHevac B (recombinant) vaccine 20 µg with inoculations occurring
at 0, 1, 2, 4, and 12 months was compared with Hevac B (plasma)
vaccine 5 µg at 0,1,2,4, and 12 months. Outcomes included both
seroconversions and partial seroconversions at 12 months.
Seaworth 1988a
This randomised trial involved CRF patients. This trial compared
recombinant and plasma vaccines. Recombivax vaccine 20 µg administered at 0,1,and 6 months was compared with Heptavax B
(plasma) vaccine 40 µg at 0, 1, 6 months. Another comparison
involved Recombivax 40 µg at 0, 1, 6 months against Heptavax B
40 µg at 0, 1, and 6 months. We divided the data of the plasma vaccine arm in half in order to undertake the statistical comparisons.
Both seroconversions and partial seroconversions at 12 months
were reported.
Reinforced vaccination series versus three inoculation vaccination series
El-Reshaid 1994
This was a randomised, single-blinded trial assessing a reinforced
vaccination series (three inoculations plus one or more booster inoculations) against a vaccination series of three inoculations using
recombinant hepatitis B vaccine. Participants were on either peritoneal dialysis or haemodialysis. Engerix B 40 µg was administered
at 0, 1, and 6 months for one arm, while another arm received
Engerix B 40 µg at 0, 1, 2, and 6 months. This study also involved
an arm of participants receiving Engerix B 20 µg at 0, 1, 2, and 6
months but this arm was excluded for the purposes of this review.
Outcomes assessed included seroconversion at 24 months.
Jilg 1986a
This study was randomised and involved dialysis patients. Three
intervention groups were employed, assessing a primary vaccination series of three inoculations against two reinforced vaccination
campaigns utilizing a booster inoculation. Merck Sharp Dohme
recombinant vaccine 40 µg at 0, 1, and 6 months was compared
to the same vaccine dose using the schedule 0, 1, 2, 3, 4, and

5 months and to Merck Sharp Dohme recombinant vaccine 20
µg at 0, 1, 2, 3, 4, and 5 months. We divided the data of the
three inoculations arm in half in order to undertake the statistical
comparisons. Outcomes reported included seroconversions at 10
months.

Risk of bias in included studies
The methodological quality of the included trials is described in
Table 3. Of the seven trials, none reported on the generation of
the allocation sequence, although the Desmyter 1983 trial described a code used for the generation of the allocation sequence.
However, this information was found to be insufficient to determine the appropriateness of the generation of the allocation
sequence. The allocation concealment was unclear in six trials,
but one (Desmyter 1983) was found to have adequate allocation
concealment. Three trials were double blinded and used placebo
(Crosnier 1981; Desmyter 1983; Stevens 1984), and the remaining four were conducted without blinding. In five trials the number and reason for dropouts and withdrawals were either described
(Desmyter 1983; Seaworth 1988a; Stevens 1984) or mentioned
(Crosnier 1981; Jungers 1994a). The El-Reshaid 1994 trial had
given the number of dropouts and withdrawals but did not provide explanations for these occurrences, while the Jilg 1986a trial
completely failed to discuss participant withdrawals or dropouts.
The assessed methodological quality of the Jilg 1986a and ElReshaid 1994 studies was very low and the assessed methodological
quality of Jungers 1994a and Seaworth 1988a was equivalent, with
both receiving modest scores. Accordingly, none of the trials was of
high methodological quality, ie, having adequate generation of the
allocation sequence, allocation concealment, blinding, and followup. However, as the important study outcomes were well-defined
serologic responses and HBV infections, inadequate blinding may
be of less concern.

Effects of interventions
Plasma derived hepatitis B vaccine versus placebo
Rate of seroconversion
Three randomised clinical trials analysed the effectiveness of
plasma derived vaccine versus placebo with 933 persons receiving
plasma vaccine and 917 receiving placebo vaccination (Crosnier
1981; Desmyter 1983; Stevens 1984). Vaccination with plasma
derived vaccine was found to be statistically more effective than
placebo in achieving seroconversion and yielded a RR 23.00, 95%
CI 14.39 to 36.76 (Comparison 01-01). The results were homogeneous (chi square = 0.36, df = 2, P = 0.83).
Only one trial provided sufficient information on partial seroconversions (Desmyter 1983) and indicated that partial seroconversions were greater among those in the plasma vaccine group (RR
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21.52, 95% CI 10.89 to 42.53, P < 0.00001 (Comparison 0102)).
Hepatitis B infections
The use of plasma derived hepatitis B vaccine did not differ significantly from placebo in preventing active HBV infections and
yielded a RR 0.50, CI 0.20 to 1.24 (Comparison 01-03) although
a trend was seen in the direction of protection, with two studies
showing benefit (Crosnier 1981; Desmyter 1983). However, the
analysis also revealed significant heterogeneity (chi squared value
of 12.29, df = 2, P = 0.0021). Sensitivity analyses were performed
on the data from the three trials to identify a possible source of
the heterogeneity. One of the trials had a significantly larger population of persons, utilized larger dosages of vaccine, and assessed
hepatitis outcomes at two years (Stevens 1984) while the other
two trials conducted assessments at 12 and 14 months (Crosnier
1981; Desmyter 1983). The source of plasma vaccines also differed between the studies.
Adverse events and deaths
Two trials reported adverse events and deaths (Crosnier 1981;
Desmyter 1983). The use of plasma vaccine appeared to be well
tolerated with no significant increase in deaths or adverse events.
Both the group receiving plasma vaccine and the group receiving
placebo reported a large number of adverse events presumed to be
unrelated to the use of hepatitis B vaccine (Desmyter 1983) .
Recombinant versus plasma derived hepatitis B vaccine
Rate of seroconversion
Two randomised trials comparing recombinant versus plasma derived hepatitis B vaccines met the inclusion criteria (Seaworth
1988a; Jungers 1994a). A total of 101 participants were inoculated
with recombinant derived hepatitis B vaccine and 80 with plasma
derived vaccine. One study (Seaworth 1988a) involved two separate comparisons of recombinant vaccine, of differing dosages, to
plasma vaccine. For the purposes of this review, we treated these
two comparisons as separate studies and therefore we differentiated them by Seaworth 1988a and Seaworth 1988b. We halved
the control group data. Although the use of recombinant vaccine
was less effective in producing seroconversions than plasma derived vaccine, the difference was not significant (RR 0.65, 95% CI
0.28 to 1.53 (Comparison 02-01). Heterogeneity was significant
(chi square = 10.22, df = 2, P = 0.006).
We conducted sensitivity analyses to determine possible origins
of the heterogeneity. Combining the two recombinant groups in
Seaworth 1988a together to compare vaccine effectiveness, regardless of the dose of recombinant vaccine used, still tended to favour
the use of plasma vaccine, although this was not significant (RR
0.75, 95% CI 0.29 to 1.92 (Comparison 02-03)). Heterogeneity
also remained high (chi square = 9.02, df = 2, P = 0.0027). When
only the high dose of recombinant vaccine arm in Seaworth 1988a
was used to compare plasma and recombinant vaccines, heterogeneity was eliminated (chi square = 2.61, df = 1, P = 0.11) and
yielded a RR 0.96, 95% CI 0.58 to 1.57 (Comparison 02-04).
Comparison of partial and full seroconversions did not favour

the use of recombinant derived vaccine over plasma vaccine and
yielded a RR value of 0.97, 95% CI 0.69 to 1.38 (Comparison
02-02). This comparison also demonstrated homogeneity among
the studies (chi square = 3.88, df = 2, P = 0.14).
Hepatitis B infections
There was insufficient information reported in the studies of
Seaworth 1988a and Jungers 1994a to assess whether recombinant vaccines differed from plasma derived vaccines in preventing
hepatitis B infections.
Adverse events and deaths
There was insufficient information reported in the studies of
Seaworth 1988a and Jungers 1994a to assess deaths and adverse
events from receiving recombinant or plasma vaccines.
Reinforced recombinant vaccination series versus three recombinant vaccine inoculations
Rate of seroconversion
Two randomised trials compared the effectiveness of a reinforced
vaccination series with three inoculations of recombinant hepatitis B vaccine (Jilg 1986a; El-Reshaid 1994). In total 63 participants received a reinforced series of recombinant vaccine while 43
received three inoculations. One study (Jilg 1986a) involved two
separate comparisons of three inoculations of 40 µg to six inoculations of 20 µg and six inoculations of 40 µg to three inoculations of
40 µg. These two separate comparisons within the same study were
differentiated by the use of an asterisk (Jilg 1986a; Jilg 1986b). We
halved the control group data. The initial analysis yielded a RR
1.36, 95% CI 0.85 to 2.16 (Comparison 03-01) and indicated
that the reinforced series was not significantly more effective in
achieving seroconversions than three inoculations. However, only
106 patients were studied and the possibility of a type II error
cannot be excluded. Heterogeneity was insignificant (chi square =
2.59, df = 2, P = 0.27).
Hepatitis B infections
Insufficient data existed to assess whether a reinforced vaccination
series was superior to a series of three inoculations of recombinant
hepatitis B vaccine in preventing hepatitis B infections.
Adverse events and death
There was insufficient information reported in these two trials (Jilg
1986a; El-Reshaid 1994) to assess deaths and adverse events.

DISCUSSION
This is the first systematic review of the effectiveness of hepatitis
B vaccinations in CRF patients. Seroconversion following hepatitis B vaccination can be used as surrogate marker for protection
against hepatitis B (Popper 1990). The results of this review indicate that the use of plasma derived vaccine is effective in achieving seroconversion. However, reductions in HBV infections could
not be demonstrated in this population given the wide confidence intervals, the heterogeneity, and the non-significant overall
effect. Plasma vaccine is significantly more effective than placebo
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in achieving seroconversion. Recombinant vaccine may be as effective as plasma vaccine in achieving seroconversion. A significant
benefit to the use of a reinforced recombinant vaccination series
in patients with CRF over the use of three inoculations could not
be proven.
Despite a thorough search of the literature we found only seven
randomised trials matching the inclusion criteria selected for this
review. Although the search for relevant literature was extensive,
publication bias cannot be disregarded, as trials with negative results may have been less likely to be published. While the relatively
small number of included trials is a limitation of this review, the
comparisons between the use of plasma vaccine and placebo involved a large number of participants (n = 1850) (Crosnier 1981;
Stevens 1984). The included trials may not have been designed
with sufficient power to detect statistically significant differences
between HBV infections in the plasma and placebo groups as infection rates were low in some of the studies (Stevens 1984). As
infections occurred in those who had previously seroconverted, seroconversion may not be universally protective in renal failure patients (Stevens 1984). In addition, the mean period of haemodialysis did differ between Crosnier 1981 and Stevens 1984, as participants in the Stevens 1984 trial had been receiving haemodialysis
for a longer duration than those in the other trial (vaccine groups
9.9 ± 13.1 months (Crosnier 1981) and 2.1± 2.1 years (Stevens
1984), placebo groups 6.9 ± 8.6 months (Crosnier 1981) and 2.0
± 2.3 years (Stevens 1984)).
Two randomised trials compared recombinant derived vaccine
with plasma derived vaccine (Jungers 1994a; Seaworth 1988a).
Both of these trials were deemed to be of the same, but low methodological quality and both had inadequate allocation concealment.
These two trials had far fewer participants than the trials comparing plasma vaccine with placebo. One of the two studies involved
the use of two different doses of Recombivax vaccine (20 µg and 40
µg) (Seaworth 1988a). For the purpose of this analysis the plasma
arm from this study was used in two different comparisons, which
might have introduced bias into the final analysis, although the
number of participants was halved. There was significant heterogeneity between the two studies in this comparison. These two
limitations preclude the formulation of conclusions based upon
the analyses, even though it suggested that there was minimal difference experienced between using recombinant or plasma hepatitis B vaccines.
Only two trials compared the use of a reinforced series against
three inoculations of recombinant hepatitis B vaccine (El-Reshaid
1994; Jilg 1986a). Sample sizes from both studies were very small
(n = 106). The methodological quality for these two trials was
also deemed to be poor with both having inadequate allocation
concealment. The use of two differing doses of vaccine (20 µg and
40 µg) in a reinforced vaccination series (Jilg 1986a) may have
affected the outcome. Bias may have also been generated as the
arm of three inoculations of 40 µg in one trial was involved in two

comparisons, although the number of participants was halved. No
heterogeneity was exhibited in this analysis. With these limitations,
no benefit was found in using a reinforced vaccination series in
the CRF population.
Only three of seven included trials were double blinded (Crosnier
1981; Desmyter 1983; Stevens 1984), all of which assessed the
use of plasma derived hepatitis B vaccine against placebo. The remaining trials were not blinded. Although non-blinded observers
can introduce significant yet unintentional bias into the analysis,
the important study outcomes of well-defined serologic responses
and HBV infections indicate that inadequate blinding may be of
less concern than issues relating to allocation. None of the studies
clearly described the generation of the allocation sequence. In addition, allocation concealment was found to be inadequate for all
of the studies with the exception of one (Desmyter 1983). This,
ultimately limits the interpretability of the analyses undertaken in
this review.
While this review found that the use of plasma derived hepatitis B
vaccines produced seroconversions that did not differ significantly
from recombinant derived vaccines, the current use of plasma vaccines is controversial. Plasma derived vaccines are human blood
products and theoretically have the potential for producing adverse
effects including blood borne infections. One study (Stevens 1984)
observed 101 cases of non-A, non-B hepatitis, which was likely
hepatitis C, occurring in both the plasma vaccine and placebo cohorts.
Current practice in North American and European dialysis centres
is to use a reinforced vaccination series of four inoculations of
Engerix B (40 µg) vaccine for those over 20 years of age (Rangel
2000; CDC 2001). The results of this review do not support this
practice. However, the limited number of randomised trials, the
low methodological quality of assessed trials, and the relatively
low number of participants in these trials are obvious limitations
hindering the formulation of clear conclusions.
The ideal dosing schedule is uncertain. The current review does
not support the administration of more than three doses of vaccine. However, as previously discussed, there are concerns with the
quality of this finding. Given the knowledge that CRF patients
on haemodialysis have impaired immune response mechanisms
(Girndt 2002), it is prudent to determine the adequacy of vaccination in each patient following the third inoculation so that supplemental inoculations can be administered if needed. Further randomised clinical trials of good methodological quality are needed
to resolve this issue. Additional factors that need to be considered
in determining the effectiveness of hepatitis B vaccination in this
population include the dosage of vaccine, the route of administration, and the use of adjuvants.

AUTHORS’ CONCLUSIONS
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Implications for practice
Plasma derived hepatitis B vaccines are clearly more effective at
achieving anti-HBs antibodies than placebo. No statistically significant difference was found between the use of recombinant or
plasma vaccine. However, given the theoretical potential for transmission of blood born pathogens with plasma derived vaccines,
recombinant vaccines remain the vaccine of choice in high-income
nations. Overall, hepatitis B vaccines, both plasma derived and
recombinant yeast derived, are effective in achieving seroconversions, although two of the three studies of plasma vaccine showed
short term benefits in preventing HBV infections. This review did
not show that either vaccine prevents HBV infections in chronic
renal failure patients.
No statistically significant difference of effectiveness was observed
between reinforced vaccination series and routine vaccinations of
three inoculations using recombinant derived vaccine.

clinical trials. Future randomised clinical trials with large sample
sizes are encouraged to compare plasma derived vaccines with recombinant vaccines among persons with impaired immunity.
Further randomised clinical trials of high methodological quality addressing a reinforced vaccination series (three inoculations
plus one or more booster inoculations) of recombinant hepatitis
B vaccines against a vaccination series of three inoculations plus
placebo booster inoculations would be of benefit to determine the
most optimal schedule for attaining seroconversion. To date there
are insufficient randomised trials on which to formulate clinical
practice recommendations. Future directions in enhancing hepatitis B vaccine effectiveness in chronic renal failure patients may
involve the use of adjuvants. As this review did not assess route
of administration, or compare differing doses of vaccines, these
issues require future investigation. Future trials ought to adopt
the CONSORT Guidelines (Consolidated Standards of Reporting Trials) (CONSORT Statement) in their reporting.

There is still insufficient information on adverse effects among
chronic renal failure patients but the data reviewed do not indicate
that vaccinations cause harm.

Implications for research
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CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]
Crosnier 1981
Methods

Randomised clinical trial, double-blind, placebo controlled, withdrawals/dropouts discussed.
43 dropouts.
* For assessment of methodological quality, please see Additional Table 04

Participants

Haemodialysis patients.

Interventions

Institut Pasteur production vaccine (plasma) 5 µg at 0,1, and 2 months versus placebo at 0,1, and 2
months

Outcomes

Anti-HBs seroconversion active hepatitis B infections, and adverse events, deaths at 12 months

Notes

Plasma vaccine versus placebo.

Risk of bias
Item

Authors’ judgement

Description

Allocation concealment?

Unclear

B - Unclear

Desmyter 1983
Methods

Randomised clinical trial, double-blind, placebo controlled, withdrawals/dropouts discussed.
13 dropouts.
* For assessment of methodological quality, please see Additional Table 04

Participants

Haemodialysis patients
(vaccine = 94 > 1 year, placebo = 80 > 1 year).

Interventions

CLB (plasma) vaccine 3 µg at 0, 1, 2, and 5 versus placebo at 0, 1, 2, and 5 months

Outcomes

Anti-HBs seroconversion, partial seroconversion, active hepatitis B infections, adverse events, deaths at
14 months

Notes

Plasma vaccine versus placebo.

Risk of bias
Item

Authors’ judgement

Description

Allocation concealment?

Yes

A - Adequate
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El-Reshaid 1994
Methods

Randomised clinical trial, single-blinded, withdrawals/dropouts discussed.
9 dropouts.
* For assessment of methodological quality, please see Additional Table 04

Participants

Peritoneal and haemodialysis patients.

Interventions

Engerix B (recombinant) 40 µg at 0, 1, and 6 versus Engerix B (recombinant) 40 µg at 0, 1, 2, and 6
months.
(Also Engerix B (recombinant) 20 µg at 0, 1, and 6 months was assessed, but this arm was excluded for the
purposes of this review as this was for healthy staff and not related to the 3 inoculation versus reinforced
series debate)

Outcomes

Anti-HBs seroconversion, active infections at 24 months.

Notes

Recombinant vaccine schedule.

Risk of bias
Item

Authors’ judgement

Description

Allocation concealment?

Unclear

B - Unclear

Jilg 1986a
Methods

Randomised clinical trial, not blinded.
* For assessment of methodological quality, please see Additional Table 04

Participants

Dialysis patients.

Interventions

Merck Sharp Dohme (recombinant) 40 µg at 0, 1, 6 versus Merck Sharp Dohme (recombinant) 40 µg at
0, 1, 2, 3, 4, and 5 months
Merck Sharp Dohme (recombinant) 40 µg at 0, 1, 6 versus Merck Sharp Dohme (recombinant) 20 µg at
0, 1, 2, 3, 4, 5

Outcomes

Anti-HBs seroconversion at 10 months.

Notes

Recombinant vaccine schedule (groups 1 and 3 combined).
Recombinant vaccine schedule (groups 1 and 2 combined).

Risk of bias
Item

Authors’ judgement

Description

Allocation concealment?

Unclear

B - Unclear

Hepatitis B vaccination for patients with chronic renal failure (Review)
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Jilg 1986b
Methods

Please see Jilg 1986a

Participants
Interventions
Outcomes
Notes
Risk of bias
Item

Authors’ judgement

Description

Allocation concealment?

Unclear

B - Unclear

Jungers 1994a
Methods

Randomised clinical trial, withdrawals/dropouts discussed.
16 dropouts.
(Not blinded)
* For assessment of methodological quality, please see Additional Table 04

Participants

Chronic uremic patients (not on dialysis).

Interventions

Hevac B (plasma) vaccine 5 µg at 0, 1, 2, 4, and 12 months versus GenHevac B (recombinant) vaccine
20 µg at 0, 1, 2, 4, and 12 months

Outcomes

Anti-HBs seroconversion, partial seroconversion at 12 months

Notes

Recombinant versus plasma.

Risk of bias
Item

Authors’ judgement

Description

Allocation concealment?

Unclear

B - Unclear

Seaworth 1988a
Methods

Randomised clinical trial, withdrawals/dropouts, discussed.
8 dropouts.
(Not blinded)
* For assessment of methodological quality, please see Additional Table 04

Participants

Chronic renal failure patients (mean 4.5 mg/dL, range 2.0 to 9.8)

Hepatitis B vaccination for patients with chronic renal failure (Review)
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Seaworth 1988a

(Continued)

Interventions

Recombivax (recombinant) vaccine 20 ug at 0, 1, 6 months versus recombivax (recombinant) vaccine 40
ug at 0, 1, 6 months versus heptavax B (plasma) vaccine 40 µg at 0, 1, 6 months

Outcomes

Anti-HBs seroconversion, partial seroconversion, deaths at 12 months

Notes

Recombinant versus plasma (groups 1 and 3 combined).
Recombinant versus plasma (groups 2 and 3 combined).

Risk of bias
Item

Authors’ judgement

Description

Allocation concealment?

Unclear

B - Unclear

Seaworth 1988b
Methods

Please see Seaworth 1988a

Participants
Interventions
Outcomes
Notes
Risk of bias
Item

Authors’ judgement

Description

Allocation concealment?

Unclear

B - Unclear

Stevens 1984
Methods

Randomised clinical trial, double-blind, placebo controlled, withdrawals/dropouts discussed.
98 dropouts.
* For assessment of methodological quality, please see Additional Table 04

Participants

Haemodialysis patients
N = 1311.

Interventions

Heptavax B (plasma) vaccine 40 µg at 0, 1, and 6 months versus placebo at 0, 1, and 6 months

Outcomes

Anti-HBs seroconversion, active hepatitis B infections, deaths at 24 months

Notes

Plasma versus placebo.

Hepatitis B vaccination for patients with chronic renal failure (Review)
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Stevens 1984

(Continued)

Risk of bias
Item

Authors’ judgement

Description

Allocation concealment?

Unclear

B - Unclear

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Andre 1987

A randomised clinical trial of 6100 people of which 270 were on chronic haemodialysis (plasma derived vaccine
20 µg at 0, 1, and 6 months or 0, 1, 2, and 12 months versus recombinant vaccine 2.5 µg, 5 µg, 10 µg, 20 µg
at 0, 1, and 6 months or 0, 1, 2, and 12 months).
We were unable to extract data specific to haemodialysis patients from the results presented in this publication

Chang 1996

A randomised clinical trial of recombinant vaccine of different doses, schedules, and routes (HepB-DNA 40 µg
at 0,1,and 3 months intramuscularly versus HepB-DNA 10 µg at 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 months
intracutaneously). This trial was excluded because it assessed route of vaccine administration

Charest 2000

A randomised clinical trial of recombinant vaccines of different routes, doses, and schedules (Engerix B 40 µg
at 0, 1, 2, and 6 months intramuscularly versus recombinant hepatitis B vaccine 5 µg intradermally at 0 month;
then every two weeks until adequate titres at least 1000 IU/L or until 2 years). This trial was excluded because
it assessed route of vaccine administration

Jungers 1994b

A randomised clinical trial of recombinant vaccine with interleukin-2 among non-responders. This trial involved
the use of an adjuvant and was therefore excluded

Propst 1998

A randomised clinical trial of recombinant vaccine of different dose, schedule, and route (Engerix B 40 µg
IM at 0, 1, and 6 months and booster at 8 and 12 months if titres less than 10 IU/L versus Engerix B 20 µg
subcutaneously every two weeks up to 240 µg versus Engerix B 20 µg intradermally every 2 weeks up to 240
µg). This trial was excluded because it assessed route of vaccine administration

Vincent 1998

A randomised clinical trial of recombinant vaccine of different dose, route and schedule (40 µg intramuscularly
at 0, 4, and 8 months versus 20 µg intradermally at 0, 0.25, 0.5, 0.75, 1, and 1.25 months). This trial was
excluded because it assessed route of vaccine administration

Vlassopoulos 1999

A randomised clinical trial of recombinant vaccine of different dose, route and schedule (Engerix, SKB 5 µg
intradermally at 0, 0.5, 1, 1.5, 2, 2.5, 3, and 3.5 months and intramuscular booster at 12 versus Engerix, SKB
20 µg intramuscularly at 0, 1, 2, and 12 months). This trial was excluded because it assessed route of vaccine
administration
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DATA AND ANALYSES

Comparison 1. Plasma vaccine versus placebo

Outcome or subgroup title
1 Seroconversion to anti-HBs
2 Full and partial anti-HBs
seroconversion
3 Hepatitis B virus infection
4 Adverse events
5 Deaths
6 Sensitivity analysis for hepatitis
B virus (HBV) infection
excluding Stevens 1984

No. of
studies

No. of
participants

3
1

1850
401

Risk Ratio (M-H, Random, 95% CI)
Risk Ratio (M-H, Random, 95% CI)

23.00 [14.39, 36.76]
21.52 [10.89, 42.52]

3
2
2
2

1850
539
539
539

Risk Ratio (M-H, Random, 95% CI)
Risk Ratio (M-H, Random, 95% CI)
Risk Ratio (M-H, Random, 95% CI)
Risk Ratio (M-H, Random, 95% CI)

0.50 [0.20, 1.24]
0.71 [0.25, 2.05]
1.39 [0.79, 2.44]
0.33 [0.18, 0.62]

Statistical method

Effect size

Comparison 2. Recombinant vaccine versus plasma vaccine

Outcome or subgroup title
1 Anti-HBs seroconversion
2 Full and partial seroconversion
to anti-HBs
3 Sensitivity analysis for anti-HBs
seroconversion - combining
both recombinant arms of
Seaworth 1988
4 Sensitivity analysis for anti-HBs
seroconversion (excluding the
low dose recombinant arm of
Seaworth 1988)

No. of
studies

No. of
participants

3
3

181
181

Risk Ratio (M-H, Random, 95% CI)
Risk Ratio (M-H, Random, 95% CI)

0.65 [0.28, 1.53]
0.97 [0.69, 1.38]

2

181

Risk Ratio (M-H, Random, 95% CI)

0.75 [0.29, 1.92]

2

160

Risk Ratio (M-H, Random, 95% CI)

0.96 [0.58, 1.57]

Statistical method

Effect size

Comparison 3. Reinforced recombinant vaccination series versus primary recombinant vaccination series

Outcome or subgroup title

No. of
studies

No. of
participants

1 Seroconversion to anti-HBs

3

106

Statistical method
Risk Ratio (M-H, Random, 95% CI)
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Analysis 1.1. Comparison 1 Plasma vaccine versus placebo, Outcome 1 Seroconversion to anti-HBs.
Review:

Hepatitis B vaccination for patients with chronic renal failure

Comparison: 1 Plasma vaccine versus placebo
Outcome: 1 Seroconversion to anti-HBs

Study or subgroup

Plasma vaccine

Placebo

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

26/72

0/66

2.8 %

48.64 [ 3.02, 782.61 ]

Desmyter 1983

148/201

6/200

35.0 %

24.54 [ 11.11, 54.21 ]

Stevens 1984

239/660

11/651

62.2 %

21.43 [ 11.83, 38.84 ]

933

917

100.0 %

23.00 [ 14.39, 36.76 ]

Crosnier 1981

Total (95% CI)

Total events: 413 (Plasma vaccine), 17 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 13.11 (P < 0.00001)

0.001 0.01 0.1

1

Favours Placebo

10 100 1000
Favours Plasma

Analysis 1.2. Comparison 1 Plasma vaccine versus placebo, Outcome 2 Full and partial anti-HBs
seroconversion.
Review:

Hepatitis B vaccination for patients with chronic renal failure

Comparison: 1 Plasma vaccine versus placebo
Outcome: 2 Full and partial anti-HBs seroconversion

Study or subgroup

Desmyter 1983

Total (95% CI)

Plasma vaccine

Placebo

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

173/201

8/200

100.0 %

21.52 [ 10.89, 42.52 ]

201

200

100.0 %

21.52 [ 10.89, 42.52 ]

Total events: 173 (Plasma vaccine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 8.83 (P < 0.00001)

0.01

0.1

Favours Placebo

1

10

100

Favours Plasma
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Analysis 1.3. Comparison 1 Plasma vaccine versus placebo, Outcome 3 Hepatitis B virus infection.
Review:

Hepatitis B vaccination for patients with chronic renal failure

Comparison: 1 Plasma vaccine versus placebo
Outcome: 3 Hepatitis B virus infection

Study or subgroup

Plasma vaccine

Placebo

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

Crosnier 1981

10/72

21/66

32.9 %

0.44 [ 0.22, 0.86 ]

Desmyter 1983

7/201

30/200

30.7 %

0.23 [ 0.10, 0.52 ]

35/660

32/651

36.3 %

1.08 [ 0.68, 1.72 ]

933

917

100.0 %

0.50 [ 0.20, 1.24 ]

Stevens 1984

Total (95% CI)

Total events: 52 (Plasma vaccine), 83 (Placebo)
Heterogeneity: Tau2 = 0.54; Chi2 = 12.29, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 1.49 (P = 0.14)

0.1 0.2

0.5

1

Favours Plasma

2

5

10

Favours Placebo

Analysis 1.4. Comparison 1 Plasma vaccine versus placebo, Outcome 4 Adverse events.
Review:

Hepatitis B vaccination for patients with chronic renal failure

Comparison: 1 Plasma vaccine versus placebo
Outcome: 4 Adverse events

Study or subgroup

Crosnier 1981
Desmyter 1983

Total (95% CI)

Plasma vaccine

Placebo

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

2/72

6/66

28.1 %

0.31 [ 0.06, 1.46 ]

111/201

111/200

71.9 %

1.00 [ 0.83, 1.19 ]

273

266

100.0 %

0.71 [ 0.25, 2.05 ]

Total events: 113 (Plasma vaccine), 117 (Placebo)
Heterogeneity: Tau2 = 0.40; Chi2 = 2.22, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 0.62 (P = 0.53)

0.01

0.1

Favours Plasma

1

10

100

Favours Placebo
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Analysis 1.5. Comparison 1 Plasma vaccine versus placebo, Outcome 5 Deaths.
Review:

Hepatitis B vaccination for patients with chronic renal failure

Comparison: 1 Plasma vaccine versus placebo
Outcome: 5 Deaths

Study or subgroup

Crosnier 1981
Desmyter 1983

Total (95% CI)

Plasma vaccine

Placebo

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

5/72

3/66

16.3 %

1.53 [ 0.38, 6.15 ]

22/201

16/200

83.7 %

1.37 [ 0.74, 2.53 ]

273

266

100.0 %

1.39 [ 0.79, 2.44 ]

Total events: 27 (Plasma vaccine), 19 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)

0.1 0.2

0.5

Favours Plasma

1

2

5

10

Favours Placebo
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Analysis 1.6. Comparison 1 Plasma vaccine versus placebo, Outcome 6 Sensitivity analysis for hepatitis B
virus (HBV) infection excluding Stevens 1984.
Review:

Hepatitis B vaccination for patients with chronic renal failure

Comparison: 1 Plasma vaccine versus placebo
Outcome: 6 Sensitivity analysis for hepatitis B virus (HBV) infection excluding Stevens 1984

Study or subgroup

Plasma vaccine

Placebo

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

Crosnier 1981

10/72

21/66

55.8 %

0.44 [ 0.22, 0.86 ]

Desmyter 1983

7/201

30/200

44.2 %

0.23 [ 0.10, 0.52 ]

Total (95% CI)

273

266

100.0 %

0.33 [ 0.18, 0.62 ]

Total events: 17 (Plasma vaccine), 51 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 1.44, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 3.48 (P = 0.00049)

0.01

0.1

1

Favours Plasma

10

100

Favours Placebo

Analysis 2.1. Comparison 2 Recombinant vaccine versus plasma vaccine, Outcome 1 Anti-HBs
seroconversion.
Review:

Hepatitis B vaccination for patients with chronic renal failure

Comparison: 2 Recombinant vaccine versus plasma vaccine
Outcome: 1 Anti-HBs seroconversion

Study or subgroup

Recombinant vaccine

Plasma vaccine

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

43/60

37/60

41.8 %

1.16 [ 0.90, 1.50 ]

Seaworth 1988a

9/20

6/10

33.5 %

0.75 [ 0.37, 1.51 ]

Seaworth 1988b

3/21

7/10

24.7 %

0.20 [ 0.07, 0.63 ]

Total (95% CI)

101

80

100.0 %

0.65 [ 0.28, 1.53 ]

Jungers 1994a

Total events: 55 (Recombinant vaccine), 50 (Plasma vaccine)
Heterogeneity: Tau2 = 0.43; Chi2 = 10.22, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 0.98 (P = 0.33)

0.1 0.2

0.5

1

Favours Plasma
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Analysis 2.2. Comparison 2 Recombinant vaccine versus plasma vaccine, Outcome 2 Full and partial
seroconversion to anti-HBs.
Review:

Hepatitis B vaccination for patients with chronic renal failure

Comparison: 2 Recombinant vaccine versus plasma vaccine
Outcome: 2 Full and partial seroconversion to anti-HBs

Study or subgroup

Recombinant vaccine

Plasma vaccine

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

Jungers 1994a

48/60

40/60

52.4 %

1.20 [ 0.96, 1.49 ]

Seaworth 1988a

12/20

7/10

25.5 %

0.86 [ 0.50, 1.47 ]

Seaworth 1988b

10/21

7/10

22.1 %

0.68 [ 0.37, 1.25 ]

Total (95% CI)

101

80

100.0 %

0.97 [ 0.69, 1.38 ]

Total events: 70 (Recombinant vaccine), 54 (Plasma vaccine)
Heterogeneity: Tau2 = 0.05; Chi2 = 3.88, df = 2 (P = 0.14); I2 =48%
Test for overall effect: Z = 0.16 (P = 0.87)

0.01

0.1

1

Favours Plasma
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Analysis 2.3. Comparison 2 Recombinant vaccine versus plasma vaccine, Outcome 3 Sensitivity analysis for
anti-HBs seroconversion - combining both recombinant arms of Seaworth 1988.
Review:

Hepatitis B vaccination for patients with chronic renal failure

Comparison: 2 Recombinant vaccine versus plasma vaccine
Outcome: 3 Sensitivity analysis for anti-HBs seroconversion - combining both recombinant arms of Seaworth 1988

Study or subgroup

Recombinant vaccine

Plasma vaccine

n/N

n/N

Jungers 1994a

43/60

37/60

53.7 %

1.16 [ 0.90, 1.50 ]

Seaworth 1988a

12/41

13/20

46.3 %

0.45 [ 0.25, 0.80 ]

101

80

100.0 %

0.75 [ 0.29, 1.92 ]

Total (95% CI)

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

Total events: 55 (Recombinant vaccine), 50 (Plasma vaccine)
Heterogeneity: Tau2 = 0.41; Chi2 = 9.02, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.60 (P = 0.55)

0.1 0.2

0.5

1

Favours Plasma

2

5

10

Favours Recombinant

Analysis 2.4. Comparison 2 Recombinant vaccine versus plasma vaccine, Outcome 4 Sensitivity analysis for
anti-HBs seroconversion (excluding the low dose recombinant arm of Seaworth 1988).
Review:

Hepatitis B vaccination for patients with chronic renal failure

Comparison: 2 Recombinant vaccine versus plasma vaccine
Outcome: 4 Sensitivity analysis for anti-HBs seroconversion (excluding the low dose recombinant arm of Seaworth 1988)

Study or subgroup

Recombinant vaccine

Plasma vaccine

n/N

n/N

43/60

37/60

63.0 %

1.16 [ 0.90, 1.50 ]

9/20

13/20

37.0 %

0.69 [ 0.39, 1.24 ]

80

80

100.0 %

0.96 [ 0.58, 1.57 ]

Jungers 1994a
Seaworth 1988a

Total (95% CI)

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

Total events: 52 (Recombinant vaccine), 50 (Plasma vaccine)
Heterogeneity: Tau2 = 0.08; Chi2 = 2.61, df = 1 (P = 0.11); I2 =62%
Test for overall effect: Z = 0.16 (P = 0.87)

0.1 0.2

0.5

1

Favours Plasma
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Analysis 3.1. Comparison 3 Reinforced recombinant vaccination series versus primary recombinant
vaccination series, Outcome 1 Seroconversion to anti-HBs.
Review:

Hepatitis B vaccination for patients with chronic renal failure

Comparison: 3 Reinforced recombinant vaccination series versus primary recombinant vaccination series
Outcome: 1 Seroconversion to anti-HBs

Study or subgroup

Reinforced series

Primary series

n/N

n/N

El-Reshaid 1994

15/24

7/24

34.4 %

2.14 [ 1.07, 4.30 ]

Jilg 1986a

12/20

5/9

35.2 %

1.08 [ 0.54, 2.14 ]

Jilg 1986b

10/19

5/10

30.4 %

1.05 [ 0.50, 2.23 ]

63

43

100.0 %

1.36 [ 0.85, 2.16 ]

Total (95% CI)

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

Total events: 37 (Reinforced series), 17 (Primary series)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.59, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 1.28 (P = 0.20)

0.2

0.5

Favours Standard

1

2

5

Favours Reinforced

ADDITIONAL TABLES
Table 1. Criteria for assessing anti-HBs response (North America)

Response

Sample ratio units (SRU)

International units (IU/L)

Inadequate

2.1 - 9.9 SRU

2.1 - 9.9 IU/L

Adequate

> 10 SRU

> 10 IU/L
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Table 2. Criteria for assessing anti-HBs response (Europe)

Response

Sample ratio units (SRU)

International units (IU/L)

Inadequate

2.1 - 9.9 SRU

2.1 - 9.9 IU/L

Low response
Adequate

10 - 100 IU/L
> 10 SRU

> 100 IU/L

Table 3. Methodological quality of included studies

Included study

Generation of allocation Allocation concealment
sequence

Blinding

Crosnier 1981

Unclear - not described.

Adequate double blinded Number and reason for
and placebo controlled.
dropouts and withdrawals
mentioned.

Desmyter 1983

Unclear - not described. A Adequate. An indepen- Adequate double blinded Number and reason for
code was used, however, dent physician had sole ac- and placebo controlled.
dropouts described.
this was insufficient infor- cess to the code
mation to determine appropriateness

El-Reshaid 1994

Unclear - not described.

Unclear

Not double blinded.

Number of dropouts and
withdrawals given but not
reasons.

Jilg 1986

Unclear - not described.

Unclear

Not double blinded.

Number and reasons for
dropouts and withdrawals
not reported

Jungers 1994

Unclear - not described.

Unclear

Not double blinded.

Number and reasons for
dropouts and withdrawals
mentioned.

Seaworth 1988

Unclear - not described.

Unclear

Not double blinded.

Number and reasons for
dropouts and withdrawals
described.

Stevens 1984

Unclear - not described.

Unclear

Adequate double blinded Number and reasons for
and placebo controlled.
dropouts and withdrawals
described.

Unclear
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APPENDICES
Appendix 1. Search Strategies

Database

Search strategy

Search performed

The Cochrane Hepato-Biliary Group Con- (’renal failure’ or ’kidney failure’ or ’renal October 2002
trolled Trials Register
disease’ or ’kidney disease’ or dialysis or
h*emodialysis) and ’hepatitis b’ and (vaccin* or immun* or booster or re-vaccin*
or revaccin*) or (engerix or heptavax or recombivax)
PubMed/MEDLINE MESH Terms

kidney[MESH];
renal
dial- July 2003
ysis[MESH]; dialysis[MESH], peritoneal
dialysis, continuous ambulatory[MESH];
dialysis, peritoneal[MESH]; kidney failure,
chronic[MESH}; kidney failure[MESH];
uremia[MESH]; hepatitis B[MESH]; hepatitis B surface antigens[MESH]; antigens, surface[MESH]; hepatitis B core
antigens[MESH]; hepatitis B e antigens[MESH]; hepatitis B surface antigens[MESH]; vaccine[MESH]; hepatitis
B vaccines[MESH]; vaccination[MESH];
immunization, secondary[MESH]; immunity[MESH]; immune sera[MESH];
vaccine, hepatitis B[MESH]; adjuvants,
immunologic[MESH]; adjuvants, pharmaceutic[MESH]; randomized controlled
trial[MESH]

PubMed/MEDLINE Search Strategy

(renal OR kidney OR kidney[MESH] July 2003
OR “renal dialysis”[MESH] OR dialysis
OR dialysis[MESH] OR hemodialysis OR
haemodialysis OR CAPD OR “continuous
ambulatory peritoneal dialysis” OR CCPD
OR “continuous cyclical peritoneal dialysis” OR ESRD OR “end stage renal disease” OR “chronic renal failure” OR “renal
failure” OR ESRF OR “end stage renal failure” OR “chronic renal insufficiency” OR
“renal insufficiency” OR “peritoneal dialysis, continuous ambulatory”[MESH] OR
“dialysis, peritoneal”[MESH] OR “kidney failure, chronic”[MESH] OR “kidney
failure”[MESH] OR uremia OR uraemia
OR uremic OR uremia[MESH]) AND
( “hepatitis b” OR “hepatitis B”[MESH]
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(Continued)

OR “australian antigen” OR HBSAG OR
“surface antigen” OR “hepatitis b surface antigens”[MESH] OR “antigens, surface”[MESH] OR “hepatitis b core antigens”[MESH] OR “hepatitis b e antigens”[MESH] OR “hepatitis b surface antigens”[MESH]) AND ( vaccine[MESH]
OR vaccin* OR immun* OR booster OR
“re-vaccinat*” OR revaccinat* OR engerix
OR heptavax OR recombivax OR “hepatitis b vaccines”[MESH] OR “secondary vaccination” OR “viral vaccines”[MESH] OR
“viral hepatitis vaccines”[MESH] OR vaccination[MESH] OR “immunization, secondary”[MESH] OR immunity[MESH]
OR “immune sera”[MESH] OR “vaccine,
hepatitis b”[MESH] OR adjuvant* OR
“Adjuvants, Immunologic”[MESH] OR
“Adjuvants, Pharmaceutic”[MESH]) AND
(“trial” OR “clinical trial” OR “randomized controlled trial” OR “randomised controlled trial” OR “randomized controlled
trial”[MESH] OR “randomized controlled
trial.pt” OR review[pt])
EMBASE

#1 explode “chronic-kidney-disease”/ all 13 November 2003
subheadings
#2 explode “chronic-kidney-failure”/ all
subheadings
#3 explode “kidney”/ all subheadings
#4 explode “kidney-disease”/ all subheadings
#5 explode “kidney-failure”/ all subheadings
#6 explode “hemodialysis”/ all subheadings
#7 explode “continuous-ambulatory-peritoneal-dialysis”/ all subheadings
#8 explode “dialysis”/ all subheadings
#9 explode “peritoneal-dialysis”/ all subheadings
#10 explode “uremia”/ all subheadings
#11 (renal or kidney) and (failure or disease* or insufficien*)
#12 ur*emi*
#13 dialys*
#14 h*emodialys*
#15 CAPD or CCPD or ESRD or ESRF
#16 #1 or #2 or #3 or #4 or #5 or #6 or #
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(Continued)

7 or #8 or #9 or #10 or #11 or #12 or #13
or #14 or #15
#17 explode “hepatitis-B”/ all subheadings
#18 explode “hepatitis-B-antigen”/ all subheadings
#19 explode “hepatitis-B-core-antigen”/ all
subheadings
#20 explode “hepatitis-Be-antigen”/ all
subheadings
#21 explode “hepatitis-B-surface-antigen”/
all subheadings
#22 hepatitis B
#23 australian antigen
#24 HBsAg
#25 surface antigen*
#26 #17 or #18 or #19 or #20 or #21 or #
22 or #23 or #24 or #25
#27 explode “hepatitis-B-vaccine”/ all subheadings
#28 explode “vaccine”/ all subheadings
#29 explode “vaccination”/ all subheadings
#30 explode “immunization”/ all subheadings
#31 explode “immunity”/ all subheadings
#32 explode “antiserum”/ all subheadings
#33 vaccin* or immun* or booster or
re*vaccin*
#34 #27 or #28 or #29 or #30 or #31 or #
32 or #33
#35 #26 and #34
#36 energix or heptavax or recombivax
#37 #35 or #36
#38 #16 and #37
#39 random* or blind* or placebo or metaanalysis
#40 #38 and #39
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Date

Event

Description

9 November 2008

Amended

Converted to new review format.
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MeSH check words
Humans
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